Ortataxel

Drug Profile

Ortataxel

Alternative Names: BAY 59-8862; IDN 5109; SBT 101131

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Indena; State University of New York
  • Developer Indena; Spectrum Pharmaceuticals
  • Class Antineoplastics; Polycyclic bridged compounds; Taxanes
  • Mechanism of Action P-glycoprotein inhibitors; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Solid tumours
  • Discontinued Non-Hodgkin's lymphoma; Renal cell carcinoma

Most Recent Events

  • 20 Jul 2017 Ortataxel is still at phase II development stage for Solid tumours in USA (PO) (IV) (Spectrum Pharmaceuticals website, July 2017)
  • 09 Jun 2015 Ortataxel is still in phase II for Solid tumours in USA (PO, IV)
  • 09 Jun 2015 Ortataxel is available for licensing in Europe, Asia (excluding USA) - http://www.sppirx.com/340-spectrum-products-out-licensing.html
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top